Related Experiment Video
Updated: Dec 16, 2025
08:58
Isolation and Identification of Waterborne Antibiotic-Resistant Bacteria and Molecular Characterization of their Antibiotic Resistance Genes
Published on: March 3, 2023
7.5K
Initial Analysis of the Arylomycin D Antibiotics.
Yun Xuan Tan1, David S Peters1, Shawn I Walsh1
1Department of Chemistry, The Scripps Research Institute, La Jolla, California 92037, United States.
Journal of Natural Products
|July 3, 2020
Summary
Arylomycin antibiotics, including actinocarbasin, show potential against MRSA. This study corrects actinocarbasin's structure, revealing its true antibacterial scaffold and mechanism against resistant bacteria.
Area of Science:
- Natural product antibiotics
- Medicinal chemistry
- Microbiology
Background:
- Arylomycins are natural product antibiotics targeting bacterial type I signal peptidase, with potential therapeutic applications.
- Four classes (A-D) are known; previous work explored A-C, suggesting latent broad-spectrum activity.
- Actinocarbasin (arylomycin D) reportedly shows activity against Methicillin-resistant Staphylococcus aureus (MRSA).
Purpose of the Study:
- To confirm and elucidate the anti-MRSA activity of actinocarbasin.
- To synthesize and analyze actinocarbasin derivatives.
- To identify the correct structure and mechanism of action for arylomycin D.
Main Methods:
- Synthesis of novel actinocarbasin derivatives.
- Structural elucidation using spectroscopic techniques.
- Antimicrobial susceptibility testing against MRSA strains.
- Mechanism of action studies.
Main Results:
- The previously reported structure of actinocarbasin was found to be incorrect.
- A likely correct scaffold for actinocarbasin was identified.
- The confirmed scaffold demonstrated significant activity against MRSA.
- The origin and mechanism of this anti-MRSA activity were determined.
Conclusions:
- The arylomycin D class, represented by actinocarbasin, possesses confirmed anti-MRSA activity.
- Structural correction is crucial for understanding and optimizing arylomycin antibiotics.
- Further development of arylomycin derivatives could lead to new MRSA therapeutics.
